Cell and Gene Therapy Market

The Cell and Gene Therapy Market Overview — Why This Market Matters and Where It Is Heading

The global cell and gene therapy market was valued at USD 31.47 billion in 2025 and is projected to reach USD 238.94 billion by 2035, expanding at a compound annual growth rate of 23.6% over the forecast period. This trajectory places cell and gene therapy among the fastest-growing segments in the entire life sciences industry — a distinction earned not by speculative enthusiasm but by a decade of relentlessly positive clinical outcomes, a deepening regulatory approval pipeline, and the irreversible commercial commitment of the world’s largest pharmaceutical corporations. The decade spanning 2025 to 2035 will be remembered as the period in which precision medicine transitioned from academic aspiration to therapeutic mainstream.

Cell and gene therapy represents a fundamental departure from the pharmacological paradigm that has dominated medicine for the past century. Where conventional drugs manage symptoms through repeated dosing, cell and gene therapies intervene at the biological source — either replacing, repairing, or silencing the genetic or cellular defects that cause disease. Cell therapy introduces living cells into a patient’s body to perform functions that diseased or absent native cells cannot, while gene therapy delivers functional genetic material directly into a patient’s cells to correct inherited mutations, silence pathological gene expression, or endow cells with new therapeutic capabilities. These two modalities are increasingly convergent — CAR-T therapies, the commercial vanguard of the sector, are simultaneously cell therapies and gene therapies, having been manufactured through ex vivo viral transduction of a patient’s own T-cells.

The macro forces reshaping this market over the five years preceding 2025 were unprecedented in their alignment. The COVID-19 pandemic, while devastating in its public health consequences, dramatically accelerated regulatory flexibility for advanced therapies and cemented mRNA and viral vector manufacturing expertise as core pharmaceutical infrastructure. The emergency authorization of mRNA vaccines validated lipid nanoparticle delivery platforms that are now being repurposed for in vivo gene therapy. Simultaneously, the first CRISPR-based medicine — Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics — received approval in the United Kingdom, United States, and Saudi Arabia, marking a watershed moment that signaled to global capital markets that genomic editing had crossed from science fiction into commercial reality.

The geopolitical and macroeconomic context of 2025 introduces both tailwinds and complexity for market participants. Trade tariff pressures affecting biological raw materials, viral vector components, and specialized manufacturing equipment have elevated production costs for U.S. and European manufacturers while simultaneously accelerating domestic supply chain investment. China’s aggressive biosimilars and cell therapy manufacturing expansion — anchored by CDMOs including WuXi Advanced Therapies and Samsung Biologics — is reshaping global production economics and forcing Western innovators to rethink their make-versus-buy decisions. Post-pandemic normalization of clinical trial enrollment has removed a significant bottleneck that suppressed late-stage approvals between 2020 and 2022, and the resulting pipeline flush is expected to deliver fifteen to twenty new therapy approvals globally between 2025 and 2028.

The relationship between this market and broader healthcare megatrends is both reinforcing and transformative. The global burden of cancer continues to grow, with the World Health Organization projecting 35 million new cancer cases annually by 2050 — a trajectory that makes the expansion of CAR-T and engineered cell therapy indispensable rather than optional for healthcare systems managing hematologic malignancies. The rare disease imperative — driven by orphan drug incentives, patient advocacy momentum, and the ethical urgency of diseases with no alternative treatments — has made gene therapy the dominant commercial strategy for monogenic disorders affecting pediatric populations. The convergence of genomics, artificial intelligence-driven target discovery, and advanced manufacturing automation ensures that the cell and gene therapy market of 2035 will be structurally unrecognizable from the one that existed at the beginning of this forecast period.

Key Trends Reshaping the Cell and Gene Therapy Market Landscape

The Rise of Allogeneic Off-the-Shelf Cell Therapies Is Democratizing Access Beyond Elite Academic Centers. For the first decade of CAR-T commercialization, autologous therapies — manufactured individually from each patient’s own cells — dominated the market but confronted a structural access crisis. Vein-to-vein manufacturing times of four to six weeks, manufacturing failures in patients with heavily pretreated immune systems, and costs exceeding USD 400,000 per treatment limited CAR-T to academic medical centers with dedicated apheresis and infusion infrastructure. Allogeneic cell therapies, derived from healthy donor cells and manufactured at scale in centralized facilities, are dismantling these barriers. Companies including Allogene Therapeutics, Fate Therapeutics, and Cellectis have demonstrated clinical responses with off-the-shelf products in Phase I and II trials, and the sector’s manufacturing economics — potentially reducing per-patient costs by 60 to 80 percent relative to autologous approaches — have attracted over USD 3.2 billion in venture and strategic investment since 2022. The clinical and commercial realization of allogeneic therapies through 2027 will determine whether cell therapy becomes a mass-market oncology tool or remains an expensive niche.

CRISPR and Advanced Gene Editing Platforms Are Creating a New Class of Precision Medicines With Functional Curative Intent. The 2023 approval of Casgevy represented more than a single commercial milestone — it inaugurated a new era in which genomic editing is a licensed, reimbursable therapeutic modality. The mechanism driving this trend is the maturation of CRISPR-Cas9 from a research tool into a clinically validated, GMP-manufacturable therapeutic platform, combined with next-generation innovations including base editing and prime editing that dramatically reduce off-target DNA damage. Beam Therapeutics’ BEAM-101 program demonstrated that base editing can achieve precise single-nucleotide corrections without introducing double-strand DNA breaks, addressing the primary safety concern that regulators applied to first-generation CRISPR therapies. In 2025, Intellia Therapeutics became the first company to demonstrate durable in vivo CRISPR editing in humans for transthyretin amyloidosis, confirming that the technology can operate systemically without ex vivo cell extraction. The commercial consequence is a pipeline of genomic medicine candidates — currently exceeding 90 active clinical programs — addressing conditions from hereditary angioedema to HIV that have historically been incurable.

Decentralized and Automated Cell Therapy Manufacturing Is Solving the Scalability Crisis That Has Constrained CAR-T Expansion. The central commercial contradiction of CAR-T therapy has been the tension between extraordinary clinical efficacy and extraordinary manufacturing complexity. Centralized manufacturing models, in which patient cells are shipped to a single facility and returned weeks later, create logistical fragility, extend vein-to-vein times, and limit geographic access to a handful of treatment centers per country. The decentralized manufacturing trend — in which compact, automated platforms such as Lonza’s Cocoon system and Miltenyi Biotec’s CliniMACS Prodigy are deployed at point-of-care institutions — is fundamentally restructuring the supply chain. Kite Pharma and Lonza announced a decentralized CAR-T manufacturing partnership in March 2025, with pilot programs targeting eight hospital-based manufacturing nodes across Europe. These systems reduce the batch cycle to under ten days, dramatically improve patient eligibility and enrollment speed, and enable a hospital-centric economic model that aligns incentive structures between manufacturers, healthcare systems, and payers.

Outcome-Based and Value-Based Reimbursement Models Are Becoming the Commercial Framework for High-Cost Cell and Gene Therapies. The market’s ability to sustain products priced between USD 300,000 and USD 3.5 million per treatment requires reimbursement architectures that cannot be accommodated by conventional insurance frameworks designed for recurring pharmaceutical costs. The trend toward outcome-based reimbursement — in which manufacturers receive full payment only if patients achieve pre-defined clinical outcomes at specified time points — is gaining regulatory and payer acceptance across the United States, United Kingdom, and Germany. Spark Therapeutics pioneered outcomes-linked contracts for Luxturna in the U.S. as early as 2018, and by 2025 this model has become the expected commercial structure for single-administration gene therapies with curative claims. The Institute for Clinical and Economic Review has endorsed value-based frameworks for both Zynteglo and Skysona, and the Centers for Medicare and Medicaid Services is developing the Cell and Gene Therapy Access Model to establish durable federal payment infrastructure. These frameworks are not merely pricing solutions — they are the commercial architecture without which the market’s most transformative products cannot achieve sustainable commercial access.

What Is Driving Growth and What Is Holding It Back — Drivers, Restraints and Opportunities

Market Drivers

Expanding FDA and EMA Approval Pipeline Is Generating Commercial Revenue Momentum at an Unprecedented Rate. The regulatory pathway for cell and gene therapies has matured significantly since the first CAR-T approval in 2017. The FDA’s Center for Biologics Evaluation and Research maintains an active pipeline of more than 900 Investigational New Drug applications for gene therapy alone, and the agency has committed to approving ten to twenty advanced therapy products annually through 2030. In 2024, the FDA approved four new cell and gene therapy products, and the EMA’s Committee for Advanced Therapies processed twelve positive opinions. Each approval creates an immediate commercial revenue event that validates the investment thesis for the broader sector and attracts incremental capital into pipeline development.

Rising Prevalence of Hematologic Cancers Is Expanding the Addressable Patient Population for CAR-T Therapies. Leukemia, lymphoma, and multiple myeloma collectively affect over 1.3 million patients annually in the United States and European Union combined. The shift of CAR-T therapies from third-line or later use to second-line and potentially first-line treatment — supported by Bristol-Myers Squibb’s KarMMa-3 and Kite Pharma’s ZUMA-7 trial data — multiplies the addressable market by three to five times relative to the current approval scope. The commercial implication is transformative: moving CAR-T earlier in the treatment algorithm exposes a patient population an order of magnitude larger than the heavily pretreated cohort that currently receives these therapies.

Curative Gene Therapy in Rare Genetic Diseases Is Eliminating Lifetime Drug Costs and Compelling Payer Adoption. The economic argument for gene therapy in rare disease is becoming the most powerful access accelerator in pharmaceutical history. A child with spinal muscular atrophy treated with Zolgensma at a cost of USD 2.125 million avoids a lifetime of Spinraza infusions costing USD 750,000 annually. The total cost savings to healthcare systems over a patient lifetime are demonstrably positive even at premium gene therapy price points, and this arithmetic is compelling institutional payers, Medicaid programs, and national health services to establish favorable coverage policies. The commercial revenue generated by Hemgenix, Elevidys, and Roctavian is demonstrating that rare disease gene therapy can achieve blockbuster revenue — an outcome that was regarded as implausible as recently as 2020.

Massive Private and Public Capital Investment Is Funding a Deep and Diversified Pipeline That Ensures Sustained Revenue Growth. Global investment in cell and gene therapy companies exceeded USD 18.4 billion in 2024 across venture capital, equity issuances, and strategic pharmaceutical partnerships. The U.S. National Institutes of Health committed USD 2.8 billion to the NIH Somatic Cell Genome Editing program through 2027, and the ARPA-H agency has designated advanced therapies manufacturing as a national security-level priority. In Europe, the European Innovation Council allocated EUR 1.2 billion to advanced therapy medicinal product development through the Horizon Europe program. This capital concentration at both the early-stage and late-stage development levels ensures that the pipeline entering commercialization between 2028 and 2035 will be substantially larger and more diverse than the current approved product set.

Advances in AAV and Lipid Nanoparticle Manufacturing Are Reducing Production Costs and Enabling Commercial Scalability. Viral vector manufacturing — historically the most significant technical bottleneck in gene therapy commercialization — has undergone a step-change improvement in efficiency. The transition from batch manufacturing to continuous bioprocessing for AAV production has reduced cost-of-goods by approximately 40 percent since 2022. Simultaneously, the broad adoption of lipid nanoparticle delivery platforms — validated at planetary scale by COVID-19 mRNA vaccines — is enabling non-viral in vivo gene delivery that bypasses the immunogenicity and manufacturing complexity associated with viral vectors. Moderna’s forays into mRNA-based gene therapy and Arctus Biotherapeutics’ LNP optimization programs reflect the convergence of vaccine manufacturing infrastructure with therapeutic gene delivery requirements.

Artificial Intelligence and Computational Biology Are Compressing Development Timelines and Improving Target Selection Precision. The application of machine learning to target identification, vector design optimization, guide RNA efficiency prediction, and patient stratification is measurably accelerating the cell and gene therapy development cycle. DeepMind’s AlphaFold protein structure database, applied to AAV capsid engineering, has enabled novel serotype design that achieves organ-specific tropism with significantly reduced immunogenicity compared to wild-type AAV serotypes. Several major cell therapy programs now use AI-driven T-cell receptor affinity modeling to identify optimal TCR sequences before synthesis, reducing the failed construct rate in development programs by approximately 35 percent based on VMR primary research interviews with leading biotech executives. This efficiency gain is compounding — each optimized development cycle reduces the per-indication cost of bringing a therapy to market, broadening the commercially viable target universe.

Asia Pacific Regulatory Harmonization and Government-Funded Manufacturing Build-Out Are Creating New Commercial Markets Outside the United States and Europe. Japan’s PMDA conditional approval pathway, instituted as early as 2014, gave Japan a first-mover advantage in commercializing novel cell therapies. South Korea’s MFDS has followed with an expedited review framework for advanced biologics, and China’s NMPA has approved its first domestic CAR-T product — axicabtagene ciloleucel manufactured by a domestic licensee — alongside multiple domestically developed programs in parallel clinical development. India’s Central Drugs Standard Control Organisation approved its first gene therapy in 2023, and government investment in CAR-T manufacturing infrastructure at the Tata Memorial Centre in Mumbai signals a strategic commitment to domestic advanced therapy manufacturing. These developments are collectively creating a multi-polar regulatory geography that reduces U.S. and European market concentration and accelerates global revenue diversification.

Market Restraints

Prohibitive Manufacturing Costs and Process Complexity Are Constraining Margins and Patient Access Simultaneously. Autologous cell therapy manufacturing remains among the most cost-intensive processes in pharmaceutical production. Each patient batch requires dedicated apheresis collection, specialized T-cell activation, viral transduction, expansion, quality release testing, and cold-chain distribution — a process that cost USD 150,000 to USD 250,000 per patient in 2024 after a decade of optimization. The highly bespoke nature of the process makes traditional pharmaceutical manufacturing economies of scale inapplicable, creating a structural cost floor that limits the commercial viability of autologous approaches to diseases where premium pricing can be justified. For less severe indications or larger patient populations, the economics are prohibitive without a manufacturing paradigm shift.

Severe Adverse Events Including Cytokine Release Syndrome and Neurotoxicity Create Clinical Risk That Constrains Prescriber Adoption. CAR-T therapies carry a well-documented risk profile that includes cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and infections resulting from prolonged B-cell aplasia. The FDA’s boxed warning requirements for all approved CAR-T products mandate administration in facilities with intensive care capabilities, effectively restricting administration to approximately 200 qualified treatment centers in the United States. This REMS requirement eliminates community oncology — which handles over 80 percent of U.S. cancer care — as a potential prescribing channel, creating a structural access bottleneck that cannot be resolved through commercial strategy alone. The 2022 FDA investigation into T-cell malignancies following CAR-T therapy, while ultimately not leading to product withdrawals, generated prescriber uncertainty that suppressed utilization growth in 2023 and 2024.

Limited Long-Term Durability Data Creates Reimbursement Uncertainty and Payer Resistance to Single-Payment Coverage Models. Cell and gene therapies are priced as curative or functionally curative interventions, yet the therapeutic category is young enough that ten-year and fifteen-year durability data do not exist for most products. Payers are reluctant to make lump-sum payments of USD 1 million or more without actuarial confidence that clinical benefit will persist, and the uncertainty around long-term efficacy creates insurance and outcomes-based contracting complexity that slows formulary access. The median duration of follow-up for approved gene therapy products as of 2025 is approximately four years — insufficient for payers managing products they expect to fund for multi-decade patient lifetimes.

Vector Immunogenicity and Pre-Existing Antibody Titers Limit Patient Eligibility for In Vivo Gene Therapy. A significant portion of the patient population that would theoretically benefit from in vivo AAV-based gene therapy is ineligible due to pre-existing neutralizing antibodies against AAV serotypes — an immune exposure arising from natural AAV infection in the general population. Prevalence of anti-AAV9 antibodies reaches 47 percent in some demographic cohorts, and current labeling for approved AAV products excludes seropositive patients entirely. This biologic constraint limits the addressable patient population to a fraction of the diagnosed population and complicates re-dosing strategies, as patients who receive an AAV gene therapy and mount an immune response cannot receive a second administration of the same serotype. Novel synthetic and bioengineered capsids are being developed to circumvent immune recognition, but these remain predominantly preclinical in 2025.

Reimbursement Framework Fragmentation Across Markets Creates Pricing Uncertainty That Suppresses Investment in Later-Stage Development. Despite the conceptual consensus around outcomes-based reimbursement, the practical implementation of payment frameworks for cell and gene therapies varies dramatically across the United States, European Union member states, and Asia Pacific markets. Germany’s AMNOG assessment process, France’s ATU framework, and the NHS’s NICE evaluation each apply distinct evidentiary standards and payment duration models that force manufacturers to develop market-specific evidence packages and negotiate individualized outcomes contracts. This fragmentation multiplies commercial launch costs and introduces revenue timing uncertainty that makes financial modeling for late-stage programs difficult. The result is a pipeline gap — several late-stage programs with proven clinical efficacy have been deprioritized or abandoned not due to clinical failure but due to commercial access uncertainty.

Market Opportunities

Solid Tumor CAR-T Expansion Represents the Single Largest Untapped Commercial Opportunity in Oncology Medicine. Hematologic malignancies currently account for over 90 percent of approved CAR-T indications, yet solid tumors represent 85 percent of global cancer incidence. The technical barriers that have historically confined CAR-T efficacy to liquid tumors — including antigen heterogeneity, the immunosuppressive tumor microenvironment, and poor T-cell trafficking into solid tumor masses — are being systematically addressed by a convergence of armored CAR constructs, combination immune checkpoint strategies, and tumor-antigen mapping technologies. Companies including Iovance Biotherapeutics, Instil Bio, and Achilles Therapeutics are advancing tumor-infiltrating lymphocyte therapies that represent a bridging modality between liquid and solid tumor cell therapy. Investors and strategic acquirers with early-stage solid tumor cell therapy portfolios are best positioned to capture the inflection when the first solid tumor CAR-T product achieves approval — an event VMR analysis places in the 2027 to 2030 window.

In Vivo Gene Editing for Common Diseases Including Cardiovascular and Metabolic Disorders Will Open a Patient Population Orders of Magnitude Larger Than Rare Disease. The rare disease focus that has characterized gene therapy’s commercial phase through 2025 was commercially rational — small patient populations with unmet need, orphan drug incentives, and premium pricing are well-suited to early-stage technology with high manufacturing costs. However, in vivo gene editing technologies — particularly CRISPR and base editing delivered via LNP — are becoming sufficiently safe and manufacturable to contemplate applications in common chronic diseases affecting tens of millions of patients. Intellia Therapeutics’ demonstration of durable LDLR gene correction in animal models of familial hypercholesterolemia, Verve Therapeutics’ PCSK9 base editing program in humans, and Beam Therapeutics’ work in metabolic liver disease all signal that cardiovascular and metabolic applications are entering the clinical pipeline. The commercial opportunity in a single common indication like familial hypercholesterolemia exceeds the entire rare disease gene therapy market, and first-movers with validated in vivo platforms in common disease categories will command extraordinary valuations through 2035.

CDMOs and Advanced Therapy Manufacturing Technology Providers Represent a Platform Investment Opportunity Insulated From Individual Product Risk. The structural bottleneck in the cell and gene therapy market is not clinical science or regulatory access — it is manufacturing capacity and process technology. CDMOs including Lonza, Samsung Biologics, WuXi ATU, Cytovance Biologics, and Charles River Laboratories are positioned as platform-level beneficiaries regardless of which specific therapeutics succeed commercially. The cell therapy CDMO market is expected to grow at a CAGR of 18.9 percent through 2030, with demand consistently outpacing available capacity. Manufacturers of automated cell processing equipment, viral vector production systems, cryopreservation technologies, and quality analytics platforms similarly benefit from market-level growth rather than individual product success. For diversified life sciences investors seeking exposure to the cell and gene therapy megatrend without concentration risk in individual clinical programs, CDMOs and technology providers represent the most risk-adjusted investment thesis available in the sector.

How the Cell and Gene Therapy Market Divides — A Full Segmentation Analysis

Segmentation Table — Full Sub-Segment Breakdown

By Type — Cell Therapy Versus Gene Therapy and Sub-Segment Dynamics

Cell therapy commands the leading position in the global market with a 58.2 percent revenue share in 2025, underpinned by the commercial success of six FDA-approved CAR-T products and the deepening utilization of hematopoietic stem cell transplantation as a therapeutic backbone in hematology. Within the cell therapy segment, CAR-T therapies contribute the majority of commercial revenue but represent only a fraction of total cell therapy volume — mesenchymal stem cell therapies, while individually lower-priced, treat a far broader patient population across orthopedic, autoimmune, and graft-versus-host disease indications. The fastest-growing sub-type within cell therapy is allogeneic CAR-T, which is projected to grow at approximately 28 percent CAGR through 2030 as manufacturing standardization reduces costs and Phase II/III data matures.

Gene therapy holds 41.8 percent of the market in 2025 and is growing at a rate that will close the gap with cell therapy through the forecast period. In vivo gene therapy — particularly AAV-mediated delivery for hemophilia, retinal dystrophies, and spinal muscular atrophy — generates the majority of current gene therapy commercial revenue, anchored by products including Zolgensma, Luxturna, Hemgenix, and Elevidys. Gene editing represents a structurally distinct and faster-growing sub-segment, with CRISPR, base editing, and prime editing platforms advancing in conditions ranging from sickle cell disease to heterozygous familial hypercholesterolemia. The trajectory of gene editing adoption will be the single most significant determinant of the gene therapy segment’s share of total market revenue by 2035.

By Application — Oncology Leadership and the Emerging Disease Category Expansion

Oncology accounts for 51.3 percent of the cell and gene therapy market in 2025, making it by far the dominant application segment. Hematologic malignancies — including diffuse large B-cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, and follicular lymphoma — represent the core commercial indication set for approved CAR-T products. The imminent expansion into solid tumors, supported by ongoing Phase II and Phase III programs in non-small cell lung cancer, colorectal cancer, and glioblastoma, will expand the oncology application further through 2030. The commercial maturity of the oncology segment, combined with the continued early-line label expansions that are moving CAR-T into second-line treatment algorithms, ensures sustained double-digit revenue growth even as the segment’s percentage share of total market modestly declines as non-oncology applications grow.

Rare and genetic disorders represent the second-largest application segment at 22.1 percent of market revenue, but they carry the highest average revenue per patient of any application category — with gene therapy products in this segment routinely priced above USD 1 million per patient. The rare disease segment’s commercial appeal lies in its orphan drug incentives, limited competitive set, and the compelling health economic argument that a single curative treatment displaces decades of chronic care costs. The FDA’s rare pediatric disease priority review voucher program, which has generated voucher sale prices exceeding USD 100 million in secondary market transactions, provides additional commercial value to rare disease gene therapy developers that exceeds the direct revenue of the therapeutic product itself.

Autoimmune diseases represent the most rapidly expanding frontier application for cell therapy, growing at an estimated 34.1 percent CAGR as investigational CAR-T programs targeting B-cell-mediated autoimmunity demonstrate unexpected response rates. The 2024 publication of data showing complete remission in systemic lupus erythematosus patients treated with CD19-directed CAR-T at the University of Erlangen-Nuremberg generated substantial commercial interest and triggered rapid pipeline expansion by Novartis, Kyverna Therapeutics, and Cabaletta Bio. The autoimmune application represents a commercial opportunity that dwarfs the oncology market in sheer patient population size, and the potential for CAR-T to replace chronic biologic therapy in autoimmune disease would create a recurring-revenue displacement event of historic magnitude for the pharmaceutical industry.

By Delivery Vector — Viral Versus Non-Viral Dynamics and the LNP Revolution

Viral vectors remain the dominant delivery modality at 67.3 percent of market revenue in 2025, with AAV commanding the largest share within the viral vector sub-segment due to its superior safety profile, established tropism diversity, and validated clinical and regulatory track record across a growing number of approved products. Lentiviral vectors hold significant share in ex vivo cell therapy applications — notably CAR-T manufacturing, where stable genomic integration of the chimeric antigen receptor construct requires lentiviral or retroviral transduction. The viral vector segment faces a structural capacity constraint: global AAV manufacturing capacity as of 2025 remains insufficient to simultaneously supply multiple commercial programs and a large clinical pipeline, creating a competitive dynamic in which CDMO relationships and in-house viral vector manufacturing capability represent a significant strategic differentiator.

Non-viral vectors, at 32.7 percent of the delivery vector market, are growing at a faster absolute rate than viral vectors and are on a trajectory to represent a substantially higher market share by 2035. Lipid nanoparticles lead the non-viral segment, propelled by the manufacturing infrastructure and regulatory precedent established during the COVID-19 mRNA vaccine rollout. The 2024 demonstration that LNP-delivered mRNA can achieve durable gene editing in the liver for cardiovascular indications — without immunogenicity concerns limiting re-dosing — has positioned LNP as the preferred delivery modality for in vivo gene therapy approaches targeting systemic diseases. Electroporation, used predominantly in ex vivo applications for CAR-T manufacturing, represents a large sub-segment within non-viral delivery with its own manufacturing optimization trajectory.

By Distribution Channel — Access Infrastructure for Advanced Therapies

Direct sales channels account for 61.2 percent of cell and gene therapy market revenue, reflecting the operational and regulatory requirements that make traditional pharmaceutical distribution models inapplicable. CAR-T therapies must be administered under a Risk Evaluation and Mitigation Strategy program that requires institutional certification, dedicated infusion capacity, and specific adverse event management protocols — requirements that mandate direct hospital procurement relationships and preclude distributor intermediation. The direct channel also encompasses the specialized pharmacy operations that manage cold-chain coordination between manufacturing facilities and treatment centers, an operational capability that has become a competitive differentiator for manufacturers seeking to minimize vein-to-vein time variability.

Third-party distribution channels, representing 38.8 percent of market revenue in 2025, are growing in importance as the product set expands beyond REMS-controlled CAR-T therapies to include outpatient cell therapies and in-office gene therapy administration for certain ophthalmic and orthopedic indications. Specialty distributors with cold-chain competence — including AmerisourceBergen, McKesson, and Cardinal Health’s specialty biologics divisions — have invested significantly in advanced therapy logistics capabilities, and the emergence of digital order management platforms specific to cell therapy supply chains is improving tracking, chain-of-custody documentation, and patient scheduling coordination.

The highest near-term commercial opportunity identified through segmentation analysis is the intersection of allogeneic CAR-T cell therapy in hematologic oncology distributed through hospital procurement channels in the United States and Western Europe. This combination offers the largest addressable patient population, the most favorable reimbursement framework, the most mature clinical evidence base, and the most established prescriber familiarity — making it the segment with the highest probability of delivering commercial revenue above consensus expectations in the 2025 to 2028 window.

Where in the World the Cell and Gene Therapy Market Is Growing — A Regional Analysis Across All Five Geographies

North America — Why the United States Remains the Commercial and Regulatory Epicenter of the Global Cell and Gene Therapy Market

North America commands 44.8 percent of global cell and gene therapy market revenue in 2025, representing an estimated USD 14.1 billion in commercial sales, and this dominance is structural rather than cyclical. The United States is home to six of the twelve currently approved commercial CAR-T and gene therapy products globally, hosts the majority of the world’s active cell and gene therapy clinical trials, and maintains the deepest payer infrastructure and pharmaceutical benefit management ecosystem for high-cost specialty biologics. The U.S. FDA’s Regenerative Medicine Advanced Therapy designation has accelerated review timelines for over 50 active programs, and the agency’s stated commitment to processing ten to twenty advanced therapy approvals annually through 2030 provides regulatory visibility that attracts capital and pipeline development at an unmatched scale.

The United States market is simultaneously the highest-revenue and highest-cost-of-access environment in the world. CAR-T therapies are priced between USD 350,000 and USD 500,000 per treatment, with gene therapies for rare diseases ranging from USD 2.1 million for Zolgensma to USD 3.5 million for Hemgenix. Despite these price points, commercial uptake has consistently exceeded analyst consensus estimates, supported by specialty pharmacy benefit networks, outcomes-based contracting frameworks, and the clinical urgency of indications with no effective alternative treatment options. The Centers for Medicare and Medicaid Services’ Cell and Gene Therapy Access Model — launched in 2024 with voluntary state Medicaid participation — is establishing the federal reimbursement infrastructure that will be essential for commercial sustainability as the product portfolio expands.

Canada contributes a smaller but strategically significant share of North American market revenue, with Health Canada’s Advanced Therapeutic Products framework providing a regulatory pathway that is increasingly harmonized with the FDA. Canadian public payer negotiations through the Canadian Drug Review and provincial formulary committees remain challenging for ultra-high-cost therapies, but patient access programs offered by manufacturers are maintaining commercial penetration. Trade tariff impacts on raw biological materials, specialized plasticware, and viral vector manufacturing equipment sourced from Europe and Asia have added approximately 8 to 12 percent to manufacturing input costs for North American cell therapy producers since 2023, creating pressure on margins that is accelerating domestic supply chain localization investment.

Asia Pacific — Why This Region Will Capture an Increasing Share of Global Revenue Through 2035 Driven by China, Japan, South Korea, and India

Asia Pacific represents 31.4 percent of global cell and gene therapy revenue in 2025 and is growing at a regional CAGR of approximately 27.8 percent — the fastest of all five global regions. The region’s growth story is multidimensional and cannot be reduced to a single country dynamic. Japan’s PMDA conditional approval pathway, which permitted commercial sale of several cell therapy products while confirmatory clinical data was collected, established Japan as the first major market for certain advanced therapy medicinal products and created institutional knowledge among Japanese oncologists and payers that is now accelerating adoption of subsequently approved global therapies. Japan’s national health insurance system covers CAR-T therapies at defined reimbursement prices, and the domestic pipeline from companies including Takeda and Kyowa Kirin ensures continued commercial growth.

China’s role in the Asia Pacific market is transformative at both the clinical and manufacturing level. The Chinese National Medical Products Administration approved its first CAR-T therapy in 2021, and by 2025 China has approved four domestic and internationally licensed CAR-T products with a pipeline of over 300 active clinical trials representing the largest national cell therapy clinical program outside the United States. The Chinese government’s 14th Five-Year Plan designated cell and gene therapy as a strategic emerging industry, providing RMB 18 billion in subsidized manufacturing investment through state-funded industrial parks in Shanghai, Shenzhen, and Beijing’s Zhongguancun Life Science Park. Domestic CDMOs including WuXi ATU have captured significant global market share in viral vector and cell therapy manufacturing, creating an integrated supply chain that positions China as both a major commercial market and a major manufacturing exporter for cell and gene therapy inputs.

India represents an emerging but rapidly ascending market within Asia Pacific, with the Central Drugs Standard Control Organisation approving NexCAR19 — India’s first domestically developed CAR-T therapy — in October 2023. Developed at the Indian Institute of Technology Bombay and Immunoadoptive Cell Therapy Private Limited, NexCAR19’s approval at a fraction of the global CAR-T price point demonstrated that indigenous development of advanced therapies in price-sensitive markets is commercially viable. The Indian government’s National Biopharmaceutical Mission and Production-Linked Incentive scheme for biotechnology are funding manufacturing scale-up, and the combination of domestic clinical capability, price-sensitive market need, and growing outbound CDMO capacity positions India as one of the highest-growth markets in the Asia Pacific region through 2030. Southeast Asian markets including Singapore, Thailand, and South Korea are simultaneously establishing regulatory frameworks and hospital infrastructure for advanced therapy administration, creating multiple points of commercial entry for global manufacturers seeking Asia Pacific expansion.

Europe — How EU Regulatory Alignment and National Health System Capacity Are Shaping Market Access Across the Region

Europe accounted for approximately 17.2 percent of global cell and gene therapy revenue in 2025, with Germany and the United Kingdom representing the two largest national markets within the region. The European Medicines Agency’s Committee for Advanced Therapies has conditionally approved multiple cell and gene therapy products, and the EU’s Regulation 1394/2007 on advanced therapy medicinal products provides a harmonized regulatory framework that reduces the burden of national registrations across the twenty-seven EU member states. Germany’s AMNOG early benefit assessment framework has been adapted to accommodate the clinical development realities of cell and gene therapies — specifically the limited patient numbers that preclude randomized controlled trial designs in orphan disease settings — enabling reimbursement decisions based on uncontrolled clinical evidence with outcomes-based payment arrangements. France’s ATU temporary authorization program has served as an access bridge for therapies that have EMA scientific opinion but are pending pricing negotiation, ensuring patient access to products like Kymriah and Yescarta without commercial disruption.

The United Kingdom operates outside EU regulatory frameworks post-Brexit, with the Medicines and Healthcare products Regulatory Agency having established an Innovative Licensing and Access Pathway that accelerates review for novel therapeutics with significant unmet need. The NHS England’s commercial framework for cell and gene therapies — including the managed access agreements negotiated for Kymriah and the outcomes-based contract for Casgevy — has become a global reference model for outcomes-linked procurement. The UK’s position as the first jurisdiction to approve Casgevy in November 2023 conferred significant first-mover advantage to the NHS as a commercial launch market and reinforced the UK’s strategic positioning as a hub for advanced therapy regulatory and clinical development. The Clinical Research Environment investment by the National Institute for Health and Care Research ensures that UK academic medical centers remain among the world’s highest-volume sites for cell and gene therapy clinical trials.

Latin America — Emerging Market Infrastructure and Access Equity Challenges in the World’s Fastest-Urbanizing Region

Latin America represents approximately 4.2 percent of global cell and gene therapy revenue in 2025, with Brazil, Mexico, and Argentina accounting for the majority of regional commercial activity. Brazil’s ANVISA regulatory agency has approved axicabtagene ciloleucel and tisagenlecleucel, making Brazil the first Latin American country to offer approved CAR-T therapies through its unified health system, the SUS. However, the public health system’s ability to fund treatments priced above USD 400,000 per patient remains severely constrained, and commercial access is predominantly limited to private hospital networks serving upper-income patient populations. The emergence of domestic clinical trial infrastructure — supported by the Brazilian government’s CTNBio regulatory modernization and the São Paulo Research Foundation’s cell therapy programs at the Hospital das Clínicas — is building the local scientific and regulatory capability that will be essential for eventual public health system access at locally negotiated price points. Distribution infrastructure challenges, including cold-chain logistics reliability in non-metropolitan regions and qualified treatment center scarcity outside major urban centers, represent the principal structural barriers to market expansion beyond Brazil’s major cities.

Middle East and Africa — Investment-Driven Growth Markets With Government-Backed Healthcare Modernization Programs

The Middle East and Africa region contributes approximately 2.4 percent of global cell and gene therapy revenue in 2025 but is growing at an estimated 31.2 percent regional CAGR — reflecting a low base combined with substantial government-funded healthcare modernization investment across Gulf Cooperation Council markets. Saudi Arabia’s Vision 2030 healthcare transformation program has designated cell and gene therapy as a national healthcare priority, with the Saudi Food and Drug Authority approving Casgevy in February 2024 in parallel with the FDA and becoming the first Middle Eastern market to offer an approved CRISPR-based therapy. The King Faisal Specialist Hospital and Research Centre in Riyadh has established one of the region’s first dedicated cell therapy programs. The United Arab Emirates, through the Dubai Health Authority and Abu Dhabi’s healthcare investment fund, is funding CAR-T treatment center infrastructure and engaging global manufacturers for commercial launch partnerships. Africa presents a longer-term opportunity concentrated in South Africa and increasingly in Nigeria and Kenya, where private healthcare networks and growing pharmaceutical investment are creating the commercial infrastructure prerequisites for advanced therapy access.

The Competitive Landscape — Who Leads, How They Compete and What Separates the Leaders in the Cell and Gene Therapy Market

The cell and gene therapy competitive landscape in 2025 is characterized by a unique dual structure: a consolidated commercial layer dominated by five to six large pharmaceutical and biotechnology companies that hold the majority of approved products and commercial revenue, coexisting with an extremely fragmented development-stage ecosystem of over 800 companies globally pursuing pipeline programs across hundreds of indications and therapeutic modalities. The top six commercial players — Novartis, Bristol-Myers Squibb, Gilead Sciences/Kite Pharma, Johnson and Johnson/Legend Biotech, Vertex/CRISPR Therapeutics, and bluebird bio — collectively account for approximately 73 percent of 2025 commercial cell and gene therapy revenue, a concentration ratio that is somewhat lower than conventional specialty pharmaceutical markets due to the geographic and indication diversity of the approved product set.

The primary competitive strategies distinguishing market leaders from emerging challengers fall into four structural categories. First, manufacturing capability and CDMO relationship depth are creating asymmetric competitive advantages that cannot be replicated through R&D investment alone. Kite Pharma’s El Segundo manufacturing facility, combined with its announced decentralized manufacturing partnership with Lonza, has established a supply chain architecture that reduces vein-to-vein time to an industry-leading seven to nine days — a metric that directly influences physician prescribing preference in a therapeutic category where patient deterioration during manufacturing delays is a material clinical risk. Second, label expansion strategy — systematically moving approved therapies into earlier treatment lines and adjacent indications — is generating incremental commercial revenue without proportionate development cost, as existing safety profiles, manufacturing processes, and payer relationships are leveraged across expanded patient populations. Third, allogeneic platform investment is determining which companies will compete in the next commercial wave: Bristol-Myers Squibb’s acquisition of Celgene-associated allogeneic programs, Allogene’s partnership with Pfizer, and Fate Therapeutics’ licensing arrangements with ONO Pharmaceutical are each positioning for the commercial transition from autologous to off-the-shelf cell therapy that the industry consensus places between 2027 and 2030.

Company Profiles — Key Players in the Global Cell and Gene Therapy Market

Market leaders are differentiated from emerging challengers along three primary capability dimensions. First, manufacturing scale and process maturity — evidenced by consistent on-time product delivery rates exceeding 95 percent, declining manufacturing failure rates, and the operational capacity to simultaneously supply commercial demand and clinical trial programs — represent a barrier to competitive entry that cannot be closed through capital alone. Second, outcomes and real-world evidence generation programs that support label expansion, reimbursement negotiations, and prescriber confidence are producing compounding commercial value that smaller companies without commercial infrastructure cannot replicate. Third, platform breadth — the ability to pursue multiple modalities, delivery systems, and therapeutic areas from shared technological infrastructure — insulates large players from the binary clinical risk that makes single-program biotechs vulnerable to commercial destruction on individual Phase III failures. The competitive capability that will determine leadership through 2035 is integrated in vivo editing capability — the ability to develop, manufacture, and deliver systemic gene editing therapies to common disease indications at a price point compatible with broad commercial access.

Market Snapshot :

Recent Developments That Are Actively Reshaping the Cell and Gene Therapy Market

January 2025 — Johnson and Johnson and Legend Biotech Complete Carvykti Manufacturing Expansion in Raritan, New Jersey. The activation of an expanded manufacturing facility for Carvykti (ciltacabtagene autoleucel) at Legend Biotech’s Raritan, New Jersey site tripled the annual production capacity for this multiple myeloma CAR-T therapy. The expansion addresses the persistent supply constraint that limited commercial uptake following FDA approval and positions Carvykti to compete more effectively with Bristol-Myers Squibb’s Abecma in a market where supply reliability is a primary physician preference driver. The investment reflects the commercial imperative to resolve manufacturing bottlenecks before label expansion into earlier treatment lines further amplifies demand.

February 2025 — Bristol-Myers Squibb Submits KarMMa-3 Confirmatory Data to the EMA for Abecma in Relapsed or Refractory Multiple Myeloma. The EMA submission of KarMMa-3 confirmatory Phase III data for ide-cel (Abecma) represents a pivotal regulatory event for both Bristol-Myers Squibb’s multiple myeloma franchise and the broader European CAR-T reimbursement landscape. KarMMa-3’s progression-free survival benefit versus standard of care in triple-class exposed patients — if reflected in the EMA’s benefit-risk assessment — would establish a European label that facilitates Health Technology Assessment negotiations in Germany, France, and the United Kingdom on terms substantially more favorable than those applied to the original conditional approval.

March 2025 — Kite Pharma and Lonza Announce Partnership for Decentralized CAR-T Manufacturing Across Eight European Hospital Sites. The Kite-Lonza decentralized manufacturing partnership announced in March 2025 represents the most significant commercial-scale deployment of point-of-care cell therapy manufacturing to date. The program places Lonza’s Cocoon automated manufacturing platforms within eight hospital-based manufacturing units across the UK, Germany, France, and the Netherlands, targeting vein-to-vein manufacturing times below ten days. If the pilot achieves its logistics and quality targets, Kite has stated its intention to expand the model to twenty-five additional hospital sites by 2027, a deployment that would fundamentally alter the CAR-T supply chain architecture in Europe.

April 2025 — Beam Therapeutics Presents Phase I Allogeneic Base-Edited CAR-T Data Showing Durable Complete Responses in DLBCL at ASH Special Symposium. Beam Therapeutics’ April 2025 presentation of BEAM-201 data — demonstrating complete responses in relapsed/refractory diffuse large B-cell lymphoma patients treated with a multiplexed base-edited allogeneic CAR-T product — generated significant commercial and scientific attention. The data showed that base editing could achieve quadruple gene disruption without detectable off-target chromosomal rearrangements, addressing the primary safety concern associated with CRISPR-based allogeneic CAR-T manufacturing. Durable complete responses at six-month follow-up in this heavily pretreated population, if confirmed in expansion cohorts, would position BEAM-201 as a differentiated allogeneic platform with best-in-class genomic safety credentials.

August 2024 — FDA Approves Obecabtagene Autoleucel (Autolus Therapeutics) for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Marking the First UK-Developed CAR-T Therapy to Receive U.S. Approval. The FDA approval of obe-cel in August 2024 was commercially significant on multiple dimensions. It validated the UK’s cell therapy development ecosystem as a source of globally competitive advanced therapy innovation, reinforced the FDA’s commitment to approved products for ALL beyond Novartis’s Kymriah, and introduced a competitively differentiated fast-binding CAR construct that demonstrated superior persistence compared to conventional scFv-based designs in clinical comparisons. Autolus’s approval also demonstrated that mid-sized biotech companies without legacy pharmaceutical distribution infrastructure can commercialize cell therapies through specialty pharmacy partnership models.

November 2023 / Commercial Rollout Through 2025 — Casgevy Achieves Global Multi-Market Commercial Launch as the World’s First Approved CRISPR-Based Therapy. The commercial rollout of Casgevy across the United Kingdom, United States, Bahrain, and Saudi Arabia through 2024 and 2025 represents the most consequential regulatory event in the history of genomic medicine to date. The product’s approval in sickle cell disease and transfusion-dependent beta-thalassemia — two indications previously addressable only by bone marrow transplantation or lifelong transfusion dependence — established CRISPR gene editing as a validated therapeutic modality with regulatory, clinical, and commercial proof of concept. The pricing of Casgevy at USD 2.2 million per patient in the United States established a market reference that simultaneously confirmed payer willingness to fund curative CRISPR therapies and created the reimbursement precedent that subsequent gene editing products will reference in their commercial launch strategies.